Skip to main content
. 2020 Aug 11;8(2):e001065. doi: 10.1136/jitc-2020-001065

Figure 1.

Figure 1

Best PSA change from baseline in mCRPC patients treated with pembrolizumab (N=9). *partial response, **complete response